Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-infected patients initiating rescue therapy (The NUCREST study)

HIV Clinical Trials

Volumn 11, Issue 5, 2010, Pages 294-302

  Perez Molina J A ^a   Serrano, O ^b   Milinkovic, A ^c   Domingo, P ^d   Curran A ^e   Knobel, H ^f   Gaspar, G ^g   Rodrigo, A ^b   Jimenez Exposito M J ^b   Hernandez Novoa B ^a   Moreno, S ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b BRISTOL MYERS SQUIBB   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

HIV; nucleos(t)ides; rescue; virological failure

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE PLUS LAMIVUDINE; DIDANOSINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 79251611903     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1105-294     Document Type: Article

References (18)

1. Consensus document of antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010). AIDS Study Group/Spanish AIDS Plan [in Spanish]. Enferm Infecc Microbiol Clin. 2010;28(6):362. e1-91. Epub May 31, 2010.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf.
3. Clumeck N, Pozniak A, RaffiF. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71.
4. Blanco JL, Biglia A, De Lazzari E, et al. Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. AIDS. 2006;20(14):1891-1892.
5. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother. 2005;49(5):1739-1744.
6. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837-846.
7. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191(6):840-847.
8. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20(6):795-803.
9. Sproat M, Pozniak AL, Peeters M, et al. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther. 2005;10(2):357-361.
10. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188(7):992-1000.
11. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS. 2006;20(16):2051-2064.
12. Harries AD, Zachariah R, van Oosterhout JJ, et al. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis. 2010;10(1):60-65.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14(3):125-130.
14. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038-1046.
15. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535-540.
16. French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002;3(3):177-185.
17. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14(9):1171-1180.
18. Humphreys E, Hernandez LB, Rutherford G. Antiretroviral regimes for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev. 2007; (4):CD006517. doi: 10.1002/14651858. CD14006517.pub14651852.